Median time to progression in chemotherapy (chemo)-naive patients with castration-resistant prostate cancer (CRPC) treated with abiraterone acetate and low-dose prednisone (Pred).

C. J. Ryan; M. R. Smith; C. Logothetis; K. Koepfgen; M. Taplin; A. L. Harzstark; P. Kantoff; T. S. Kheoh; A. Molina; E. J. Small

doi:10.1200/jco.2010.28.15_suppl.4671

Median time to progression in chemotherapy (chemo)-naive patients with castration-resistant prostate cancer (CRPC) treated with abiraterone acetate and low-dose prednisone (Pred).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.4671 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 4671-4671

Author(s):

C. J. Ryan ◽

M. R. Smith ◽

C. Logothetis ◽

K. Koepfgen ◽

M. Taplin ◽

...

Keyword(s):

Prostate Cancer ◽

Median Time ◽

Low Dose ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Time To Progression ◽

Castration Resistant ◽

Dose Prednisone

Download Full-text

Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer

European Urology ◽

10.1016/j.eururo.2016.02.035 ◽

2016 ◽

Vol 70 (3) ◽

pp. 438-444 ◽

Cited By ~ 24

Author(s):

Karim Fizazi ◽

Kim N. Chi ◽

Johann S. de Bono ◽

Leonard G. Gomella ◽

Kurt Miller ◽

...

Keyword(s):

Prostate Cancer ◽

Adverse Events ◽

Low Dose ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Low Incidence ◽

Dose Prednisone

Download Full-text

MP50-20 IMPACT OF ABIRATERONE ACETATE IN PROSTATE SPECIFIC ANTIGEN TRIAL UPDATE: EFFECT OF ABIRATERONE ACETATE AND LOW DOSE PREDNISONE ON PROSTATE-SPECIFIC ANTIGEN AND RADIOGRAPHIC DISEASE PROGRESSION IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

The Journal of Urology ◽

10.1016/j.juro.2016.02.454 ◽

2016 ◽

Vol 195 (4S) ◽

Author(s):

Charles Ryan ◽

E. David Crawford ◽

Neal D Shore ◽

Willie Underwood ◽

Anil Londhe ◽

...

Keyword(s):

Prostate Cancer ◽

Disease Progression ◽

Prostate Specific Antigen ◽

Low Dose ◽

Specific Antigen ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Radiographic Disease ◽

Dose Prednisone

Download Full-text

564 Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (pts)

European Urology Supplements ◽

10.1016/s1569-9056(15)60557-7 ◽

2015 ◽

Vol 14 (2) ◽

pp. e564 ◽

Cited By ~ 1

Author(s):

K. Miller ◽

K. Chi ◽

J.S. De Bono ◽

K. Fizazi ◽

L.G. Gomella ◽

...

Keyword(s):

Prostate Cancer ◽

Adverse Events ◽

Low Dose ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Dose Prednisone

Download Full-text

MP87-19 EFFECT OF ABIRATERONE ACETATE AND LOW DOSE PREDNISONE ON PROSTATE-SPECIFIC ANTIGEN IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: THE RESULTS FROM IMPACT OF ABIRATERONE ACETATE IN PROSTATE-SPECIFIC ANTIGEN CORE STUDY

The Journal of Urology ◽

10.1016/j.juro.2015.02.1964 ◽

2015 ◽

Vol 193 (4S) ◽

Author(s):

Charles J. Ryan ◽

E. David Crawford ◽

Neal D. Shore ◽

Willie Underwood ◽

Jim Wang ◽

...

Keyword(s):

Prostate Cancer ◽

Prostate Specific Antigen ◽

Low Dose ◽

Specific Antigen ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Core Study ◽

Dose Prednisone

Download Full-text

Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035

European Urology ◽

10.1016/j.eururo.2016.05.004 ◽

2016 ◽

Vol 70 (2) ◽

pp. e41 ◽

Cited By ~ 2

Author(s):

Giandomenico Roviello ◽

Alberto Bottini ◽

Daniele Generali

Keyword(s):

Prostate Cancer ◽

Adverse Events ◽

Low Dose ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Low Incidence ◽

Dose Prednisone

Download Full-text

MP87-18 ASSESSMENT OF CORTICOSTEROID (CS)-ASSOCIATED ADVERSE EVENTS (AES) WITH LONG-TERM (LT) EXPOSURE TO LOW-DOSE PREDNISONE (P) GIVEN WITH ABIRATERONE ACETATE (AA) TO METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS)

The Journal of Urology ◽

10.1016/j.juro.2015.02.1963 ◽

2015 ◽

Vol 193 (4S) ◽

Cited By ~ 2

Author(s):

Leonard G. Gomella ◽

Kim N. Chi ◽

Johann S. de Bono ◽

Karim Fizazi ◽

Kurt Miller ◽

...

Keyword(s):

Prostate Cancer ◽

Adverse Events ◽

Low Dose ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Dose Prednisone

Download Full-text

IMAAGEN trial update: Effect of abiraterone acetate and low dose prednisone on PSA and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5053 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5053-5053 ◽

Cited By ~ 4

Author(s):

Charles J. Ryan ◽

E David Crawford ◽

Neal D. Shore ◽

Willie Underwood ◽

Anil Londhe ◽

...

Keyword(s):

Prostate Cancer ◽

Disease Progression ◽

Low Dose ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Radiographic Disease ◽

Dose Prednisone

Download Full-text

Effect of abiraterone acetate and low-dose prednisone on PSA in patients with nonmetastatic castration-resistant prostate cancer: The results from IMAAGEN core study.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5086 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5086-5086 ◽

Cited By ~ 4

Author(s):

Charles J. Ryan ◽

E. David Crawford ◽

Neal D. Shore ◽

Willie Underwood ◽

Jim Wang ◽

...

Keyword(s):

Prostate Cancer ◽

Low Dose ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Core Study ◽

Dose Prednisone

Download Full-text

IMAAGEN trial safety and efficacy update: Effect of abiraterone acetate and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.5061 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 5061-5061 ◽

Cited By ~ 5

Author(s):

Charles J. Ryan ◽

E. David Crawford ◽

Neal D. Shore ◽

Willie Underwood ◽

Mary-Ellen Taplin ◽

...

Keyword(s):

Prostate Cancer ◽

Prostate Specific Antigen ◽

Low Dose ◽

Specific Antigen ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Safety And Efficacy ◽

Castration Resistant ◽

Radiographic Disease ◽

Dose Prednisone

Download Full-text

Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035. Corticosteroid-associated Adverse Events in Elderly Patients

European Urology ◽

10.1016/j.eururo.2016.05.005 ◽

2016 ◽

Vol 70 (2) ◽

pp. e42 ◽

Cited By ~ 1

Author(s):

Karim Fizazi ◽

Peter De Porre ◽

Anil Londhe ◽

Tracy McGowan ◽

Charles J. Ryan

Keyword(s):

Prostate Cancer ◽

Adverse Events ◽

Elderly Patients ◽

Low Dose ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Low Incidence ◽

Dose Prednisone

Download Full-text